#erbb2
Agreement Between Medical Laboratory Technologists and Pathologists’ Assessment of ERBB2 (HER2) Fluorescence In Situ Hybridization Across Breast and Gastric Scoring Criteria www.ovid.com/10.1097/PAI....
Agreement Between Medical Laboratory... : Applied Immunohistochemistry & Molecular Morphology
ERBB2 (HER2) fluorescence in situ hybridization (FISH) guides therapy selection for solid tumors, including breast and gastric cancers. While...
www.ovid.com
November 2, 2026 at 9:58 PM
New drug shrinks tumours in 75% of advanced breast cancer cases

A targeted drug shrank tumours in more than three-quarters of patients with advanced breast cancer in a phase three trial, while significantly delaying the point at which the disease began to progress. The treatment, trastuzumab…
New drug shrinks tumours in 75% of advanced breast cancer cases
A targeted drug shrank tumours in more than three-quarters of patients with advanced breast cancer in a phase three trial, while significantly delaying the point at which the disease began to progress. The treatment, trastuzumab rezetecan, was tested in patients with ERBB2-low metastatic breast cancer – a form in which tumours contain low levels of the HER2 protein, which can help cancer cells grow.
dispatchtimes.com
October 30, 2026 at 12:14 AM
Trastuzumab rezetecan proporciona beneficios en la supervivencia libre de progresión sobre la elección de la quimioterapia en pacientes con cáncer de mama avanzado bajo en ERBB2 #trastuzumab #rezetecan #breastcancer #erbb2 jamanetwork.com/journals/jam...
Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer
This randomized, multicenter, phase 3 trial compares progression-free survival with trastuzumab rezetecan vs physician’s choice of chemotherapy in patients with ERBB2-low metastatic breast cancer.
jamanetwork.com
October 27, 2026 at 6:27 AM
Trastuzumab rezetecan extended median time without progression in advanced HER2-low breast cancer to 16.4 months versus 6.8 on chemotherapy, but severe treatment-related side effects were more common. doi.org/hcp4pk
Targeted drug significantly delays advanced breast cancer progression but increases toxicity, phase III trial reports
In a global phase 1 trial, trastuzumab rezetecan showed promising signs of fighting ERBB2-low metastatic breast cancer in patients who had already undergone extensive treatment.
medicalxpress.com
October 27, 2026 at 4:40 PM
In #ERBB2-low unresectable or metastatic #BreastCancer, trastuzumab rezetecan improved progression-free survival vs chemotherapy, with consistent benefit in both hormone receptor–positive and hormone receptor–negative disease.

📌 Learn more: ja.ma/4BoL3NT
October 23, 2026 at 3:00 PM
💡Exploring ERBB2/HER2 in cholangiocarcinoma! 🧬

Through a Virtual Mobility Grant from COST Action CA22125 (#PrecisionBTCNetwork), researchers investigated ERBB2 expression, genomic alterations, prognostic value and immune associations to advance precision oncology.
October 22, 2026 at 6:13 PM
Among African women with #BreastCancer, standard #Immunohistochemistry markers identified basal-like tumors well but often misclassified PAM50 luminal B tumors as luminal A.

ja.ma/4s9auif
October 12, 2026 at 4:15 PM
Among patients with transurethrally unresectable, ERBB2-positive #BladderCancer, disitamab vedotin plus tislelizumab was associated with high complete response and disease control, with no muscle-invasive or metastatic progression during follow-up.

ja.ma/4j8TEO5
October 10, 2026 at 2:00 PM
🔹Additional alterations more frequent in those with TP53 alterations (Y220C and non-Y220C) versus TP53wt cases included BRCA1, ERBB2, PTEN, RB1, AKT2, KRAS, MTAP, NTRK1, and VEGFA.
October 10, 2026 at 11:56 AM
Disitamab Vedotin Plus Tislelizumab in Transurethrally Unresectable, ERBB2-Positive, Non–Muscle-Invasive #BladderCancer: A Nonrandomized Clinical Trial. jamanetwork.com/journals/jam...
Disitamab Vedotin Plus Tislelizumab in Non–Muscle-Invasive Bladder Cancer
This nonrandomized clinical trial examines the efficacy of disitamab vedotin plus tislelizumab for transurethrally unresectable, ERBB2-positive, very high-risk, non–muscle-invasive bladder cancer in a...
jamanetwork.com
October 9, 2026 at 10:19 AM
By using inducible KRASG12V and ERBB2 in epithelial cysts and mice, a study finds that disrupting architectural homeostasis promotes epithelial disorganization and tumour growth.

@mcgillgci.bsky.social

www.nature.com/articles/s42...
Epithelial tissue architecture acts as a barrier to carcinoma initiation - Communications Biology
By using inducible KRASG12V and ERBB2 in epithelial cysts and, this study finds that disrupting architectural homeostasis promotes epithelial disorganization and tumor growth.
www.nature.com
October 8, 2026 at 1:55 PM
Among patients with transurethrally unresectable, ERBB2-positive #BladderCancer, disitamab vedotin plus tislelizumab was associated with high complete response and durable disease control, with no muscle-invasive or metastatic progression during follow-up.

ja.ma/479i4jj
October 8, 2026 at 3:30 PM
Knowing a gene drives a disease is not knowing how. Disease Atlas by Euretos traces the cascade: ERBB2 (HER2) in breast cancer, from EGF-ERBB2-RAS-ERK into PI3K-AKT-mTOR, to epithelial cell proliferation in the mammary epithelial cell. Mechanism, not correlation. #Oncology
October 7, 2026 at 7:02 AM
From Cancer Discovery: Sevabertinib for HER2 Alterations in Lung Cancer doi.org/10.1158/2159...
Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Sevabertinib, a non-covalent inhibitor of the HER2 kinase, shows activity in preclinical cancer models with genomic activation of ERBB2 and for patients with HER2-mutant lung cancer.
doi.org
October 6, 2026 at 3:54 PM
Congrats Sharanya! Her Clinical Cancer Research study identified ERBB2 mutations as a biomarker of trastuzumab deruxtecan response, potentially expanding treatment options for patients with breast cancer. Featured at @theaacr.bsky.social D3 2026 and highlighted in AACR's From the Bench series. 👏
October 1, 2026 at 5:30 PM
Sharanya Nag #MSKPostdoc in the @saratchandarlapaty.bsky.social Lab identifies activating ERBB2 mutations as a potential biomarker of trastuzumab deruxtecan sensitivity, expanding treatment options for patients w/metastatic breast cancer, including those with HER2 IHC 0 tumors.
#NPAW2026🇮🇳
October 1, 2026 at 5:30 PM
MEMO1–ERα interaction may occur independent of Y537 phosphorylation which differs from MEMO1-ErbB2 binding #micropublication #biology #data #caltechlibrary #Escherichiacoli #Biochemistry #Computationa https://micropublication.org/journals/biology/micropub-biology-002363
September 29, 2026 at 6:40 PM
Risk-Window Palbociclib Exposure Delays ErbB2-Driven Mammary Tumorigenesis and Suppresses Mammary Epithelial Cell Stemness https://www.biorxiv.org/content/10.64898/2026.09.14.751306v1
September 17, 2026 at 10:48 AM
Risk-Window Palbociclib Exposure Delays ErbB2-Driven Mammary Tumorigenesis and Suppresses Mammary Epithelial Cell Stemness https://www.biorxiv.org/content/10.64898/2026.09.14.751306v1
September 17, 2026 at 10:48 AM
ERBB2 establishes the timing of progesterone priming required for uterine receptivity https://www.biorxiv.org/content/10.64898/2026.09.14.751518v1
September 16, 2026 at 5:30 PM
ERBB2 establishes the timing of progesterone priming required for uterine receptivity https://www.biorxiv.org/content/10.64898/2026.09.14.751518v1
September 16, 2026 at 5:30 PM
The authors included RRIDs in their in Cell Biochemistry and Function paper! We value the author's support of reproducibility. #OpenScience #accelerateopenscience #reproducibility
S100 Calcium-Binding Protein 16 (S100A16) Promotes Hepatic Stellate Cell Activation Via Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2)-mediated Glycolysis to Facilitate Liver Fibrosis
Read the full paper: S100 Calcium-Binding Protein 16 (S100A16) Promotes Hepatic Stellate Cell Activation Via Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2)-mediated Glycolysis to Facilitate Liver Fibrosis
doi.org
September 16, 2026 at 7:33 PM